Icen, M. et al. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J. Am. Acad. Dermatol. 60, 394–401 (2009).
Damiani, G. et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front. Med. 8, 743180 (2021).
Parisi, R. et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369, m1590 (2020).
Meyer, N. et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J. Eur. Acad. Dermatol. Venereol. 24, 1075–1082 (2010).
Villacorta, R. et al. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br. J. Dermatol. 183, 548–558 (2020).
Cao, F. et al. Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019. Autoimmun. Rev. 22, 103326 (2023).
Wang, H. M., Xu, J. M. & Jin, H. Z. Characteristics and burdens of disease in patients from beijing with generalized pustular psoriasis and palmoplantar pustulosis: multicenter retrospective cohort study using a regional database. Am. J. Clin. Dermatol. https://doi.org/10.1007/s40257-023-00807-2 (2023).
Pilon, D. et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J. Med Econ. 22, 196–203 (2019).
Singh, S., Taylor, C., Kornmehl, H. & Armstrong, A. W. Psoriasis and suicidality: a systematic review and meta-analysis. J. Am. Acad. Dermatol. 77, 425–440.e422 (2017).
Matterne, U., Baumeister, S. E. & Apfelbacher, C. J. Suicidality and risk of suicidality in psoriasis: a critical appraisal of two systematic reviews and meta-analyses. Br. J. Dermatol. 181, 717–721 (2019).
Armstrong, A. W. & Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323, 1945–1960 (2020).
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E. & Barker, J. Psoriasis. Lancet 397, 1301–1315 (2021).
Patrick, M. T. et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat. Commun. 13, 6565 (2022).
Veale, D. J. & Fearon, U. The pathogenesis of psoriatic arthritis. Lancet 391, 2273–2284 (2018).
Yan, D., Afifi, L., Jeon, C., Cordoro, K. M. & Liao, W. A cross-sectional study of psoriasis triggers among different ethno-racial groups. J. Am. Acad. Dermatol. 77, 756–758.e751 (2017).
Twelves, S. et al. Clinical and genetic differences between pustular psoriasis subtypes. J. Allergy Clin. Immunol. 143, 1021–1026 (2019).
FitzGerald, O. et al. Psoriatic arthritis. Nat. Rev. Dis. Prim. 7, 59 (2021).
Chalmers, R., O’Sullivan, T., Owen, C. M. & Griffiths, C. E. WITHDRAWN: interventions for guttate psoriasis. Cochrane Database Syst. Rev. 4, Cd001213 (2019).
Carrasquillo, O. Y. et al. Treatment of erythrodermic psoriasis with biologics: a systematic review. J. Am. Acad. Dermatol. 83, 151–158 (2020).
Elmets, C. A. et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J. Am. Acad. Dermatol. 80, 1073–1113 (2019).
Kaushik, S. B. & Lebwohl, M. G. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 80, 27–40 (2019).
Korman, N. J. Management of psoriasis as a systemic disease: what is the evidence? Br. J. Dermatol. 182, 840–848 (2020).
Kim, W. B., Jerome, D. & Yeung, J. Diagnosis and management of psoriasis. Can. Fam. Phys. 63, 278–285 (2017).
Boehncke, W. H. & Schön, M. P. Psoriasis. Lancet 386, 983–994 (2015).
Bronckers, I. M., Paller, A. S., van Geel, M. J., van de Kerkhof, P. C. & Seyger, M. M. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr. Drugs 17, 373–384 (2015).
van de Kerkhof, P. C. From empirical to pathogenesis-based treatments for psoriasis. J. Invest. Dermatol. 142, 1778–1785 (2022).
Rendon, A. & Schäkel, K. Psoriasis pathogenesis and treatment. Int J. Mol. Sci. 20, 1475 (2019).
Raychaudhuri, S. P., Wilken, R., Sukhov, A. C., Raychaudhuri, S. K. & Maverakis, E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J. Autoimmun. 76, 21–37 (2017).
Coates, L. C. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat. Rev. Rheumatol. 18, 465–479 (2022).
Ghoreschi, K., Balato, A., Enerbäck, C. & Sabat, R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397, 754–766 (2021).
Kumar, R., Theiss, A. L. & Venuprasad, K. RORγt protein modifications and IL-17-mediated inflammation. Trends Immunol. 42, 1037–1050 (2021).
Conrad, C. & Gilliet, M. Psoriasis: from pathogenesis to targeted therapies. Clin. Rev. Allergy Immunol. 54, 102–113 (2018).
Deng, Y., Chang, C. & Lu, Q. The inflammatory response in psoriasis: a comprehensive review. Clin. Rev. Allergy Immunol. 50, 377–389 (2016).
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V. & Massari, L. P. Current concepts of psoriasis immunopathogenesis. Int J. Mol. Sci. 22, 11574 (2021).
Chandra, A., Ray, A., Senapati, S. & Chatterjee, R. Genetic and epigenetic basis of psoriasis pathogenesis. Mol. Immunol. 64, 313–323 (2015).
Trowbridge, R. M. & Pittelkow, M. R. Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. J. Drugs Dermatol 13, 111–118 (2014).
Blunder, S., Pavel, P., Minzaghi, D. & Dubrac, S. PPARdelta in affected atopic dermatitis and psoriasis: a possible role in metabolic reprograming. Int J. Mol. Sci. 22, 7354 (2021).
Lian, N., Shi, L. Q., Hao, Z. M. & Chen, M. Research progress and perspective in metabolism and metabolomics of psoriasis. Chin. Med. J. 133, 2976–2986 (2020).
Jiang, B., Zhang, H., Wu, Y. & Shen, Y. Single-cell immune ecosystem and metabolism reprogramming imprinted by psoriasis niche. Ann. Transl. Med. 10, 837 (2022).
Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41, 199–204 (2009).
Hüffmeier, U. et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 42, 996–999 (2010).
Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273–290 (2007).
Nair, R. P. et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J. Invest. Dermatol. 128, 1653–1661 (2008).
Langley, R. G. et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N. Engl. J. Med. 371, 326–338 (2014).
Blauvelt, A. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J. Am. Acad. Dermatol. 76, 405–417 (2017).
Merola, J. F. et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 401, 38–48 (2023).
Griffiths, C. E. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362, 118–128 (2010).
Duvallet, E., Semerano, L., Assier, E., Falgarone, G. & Boissier, M. C. Interleukin-23: a key cytokine in inflammatory diseases. Ann. Med. 43, 503–511 (2011).
Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719–729 (2015).
Yawalkar, N., Tscharner, G. G., Hunger, R. E. & Hassan, A. S. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J. Dermatol. Sci. 54, 99–105 (2009).
Sun, L., Su, Y., Jiao, A., Wang, X. & Zhang, B. T cells in health and disease. Sig. Transduct. Target Ther. 8, 235 (2023).
Li, Y., Yu, X., Ma, Y. & Hua, S. IL-23 and dendritic cells: what are the roles of their mutual attachment in immune response and immunotherapy? Cytokine 120, 78–84 (2019).
Liu, T. et al. The IL-23/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front. Immunol. 11, 594735 (2020).
Gu, C., Wu, L. & Li, X. IL-17 family: cytokines, receptors and signaling. Cytokine 64, 477–485 (2013).
Johansen, C. et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br. J. Dermatol. 160, 319–324 (2009).
Johnston, A. et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol. 190, 2252–2262 (2013).
Martin, D. A. et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J. Invest. Dermatol. 133, 17–26 (2013).
Blauvelt, A. & Chiricozzi, A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin. Rev. Allergy Immunol. 55, 379–390 (2018).
Chang, S. H. & Dong, C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 17, 435–440 (2007).
Bertelsen, T., Iversen, L. & Johansen, C. The human IL-17A/F heterodimer regulates psoriasis-associated genes through IκBζ. Exp. Dermatol. 27, 1048–1052 (2018).
McGeachy, M. J., Cua, D. J. & Gaffen, S. L. The IL-17 family of cytokines in health and disease. Immunity 50, 892–906 (2019).
Keijsers, R. R., Joosten, I., van Erp, P. E., Koenen, H. J. & van de Kerkhof, P. C. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp. Dermatol. 23, 799–803 (2014).
Brembilla, N. C., Senra, L. & Boehncke, W. H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front. Immunol. 9, 1682 (2018).
Knizkova, D. et al. CMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology. Nat. Immunol. 23, 1644–1652 (2022).
Furue, M., Furue, K., Tsuji, G. & Nakahara, T. Interleukin-17A and Keratinocytes in Psoriasis. Int J. Mol. Sci. 21, 1275 (2020).
Lo, Y. H. et al. Galectin-8 is upregulated in keratinocytes by IL-17A and promotes proliferation by regulating mitosis in psoriasis. J. Invest. Dermatol. 141, 503–511.e509 (2021).
Christmann, C. et al. Interleukin 17 promotes expression of alarmins S100A8 and S100A9 during the inflammatory response of keratinocytes. Front. Immunol. 11, 599947 (2020).
Ekman, A. K., Bivik Eding, C., Rundquist, I. & Enerbäck, C. IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis. J. Invest. Dermatol. 139, 1564–1573.e1568 (2019).
Xu, X. et al. Interleukin-17A drives IL-19 and IL-24 expression in skin stromal cells regulating keratinocyte proliferation. Front. Immunol. 12, 719562 (2021).
Liu, Y. et al. A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis. J. Dermatol. Sci. 101, 84–92 (2021).
Garzorz-Stark, N. & Eyerich, K. Psoriasis pathogenesis: keratinocytes are back in the spotlight. J. Invest. Dermatol. 139, 995–996 (2019).
Ramirez-Carrozzi, V. et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12, 1159–1166 (2011).
Borowczyk, J. et al. IL-17E (IL-25) and IL-17A differentially affect the functions of human keratinocytes. J. Invest. Dermatol. 140, 1379–1389.e1372 (2020).
Reich, K. et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br. J. Dermatol. 167, 180–190 (2012).
McGeough, M. D. et al. TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J. Clin. Invest. 127, 4488–4497 (2017).
Grine, L., Dejager, L., Libert, C. & Vandenbroucke, R. E. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 26, 25–33 (2015).
Hu, P. et al. The role of helper T cells in psoriasis. Front. Immunol. 12, 788940 (2021).
Kristensen, M. et al. Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin. Exp. Immunol. 94, 354–362 (1993).
Psarras, A. et al. TNF-α regulates human plasmacytoid dendritic cells by suppressing IFN-α production and enhancing T cell activation. J. Immunol. 206, 785–796 (2021).
Li, S. J., Perez-Chada, L. M. & Merola, J. F. TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J. Psoriasis Psoriatic Arthritis 4, 70–80 (2019).
Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183–3194 (2007).
Schottelius, A. J. et al. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp. Dermatol. 13, 193–222 (2004).
Chiricozzi, A. et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131, 677–687 (2011).
Gupta, R. K. et al. TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy. Sci. Immunol. 6, eabi8823 (2021).
Richmond, J. M., Strassner, J. P., Essien, K. I. & Harris, J. E. T-cell positioning by chemokines in autoimmune skin diseases. Immunol. Rev. 289, 186–204 (2019).
Meehan, E. V. & Wang, K. Interleukin-17 family cytokines in metabolic disorders and cancer. Genes 13, 1643 (2022).
Kim, K. E., Houh, Y., Park, H. J. & Cho, D. Therapeutic effects of erythroid differentiation regulator 1 on imiquimod-induced psoriasis-like skin inflammation. Int J. Mol. Sci. 17, 244 (2016).
Mabuchi, T. et al. CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-induced model of psoriasiform dermatitis. J. Invest. Dermatol. 133, 164–171 (2013).
Schutyser, E., Struyf, S. & Van Damme, J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14, 409–426 (2003).
Singh, S. P., Zhang, H. H., Foley, J. F., Hedrick, M. N. & Farber, J. M. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J. Immunol. 180, 214–221 (2008).
Shin, J. W. et al. Keratinocyte transglutaminase 2 promotes CCR6(+) γδT-cell recruitment by upregulating CCL20 in psoriatic inflammation. Cell Death Dis. 11, 301 (2020).
Harper, E. G. et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J. Invest. Dermatol. 129, 2175–2183 (2009).
Kennedy-Crispin, M. et al. Human keratinocytes’ response to injury upregulates CCL20 and other genes linking innate and adaptive immunity. J. Invest. Dermatol. 132, 105–113 (2012).
Furue, K. et al. Cyto/chemokine profile of in vitro scratched keratinocyte model: implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon. J. Dermatol Sci. 94, 244–251 (2019).
Johnston, A. et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 140, 109–120 (2017).
Neurath, M. F. IL-36 in chronic inflammation and cancer. Cytokine Growth Factor Rev. 55, 70–79 (2020).
Blumberg, H. et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J. Immunol. 185, 4354–4362 (2010).
Sims, J. E. & Smith, D. E. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10, 89–102 (2010).
Johnston, A. et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 186, 2613–2622 (2011).
Traks, T. et al. Polymorphisms in IL36G gene are associated with plaque psoriasis. BMC Med. Genet. 20, 10 (2019).
Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 365, 620–628 (2011).
Onoufriadis, A. et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am. J. Hum. Genet. 89, 432–437 (2011).
Zuo, X. et al. Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis. Nat. Commun. 6, 6793 (2015).
Hébert, H. L. et al. Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. J. Invest. Dermatol. 134, 1459–1462 (2014).
Gresnigt, M. S. & van de Veerdonk, F. L. Biology of IL-36 cytokines and their role in disease. Semin. Immunol. 25, 458–465 (2013).
Towne, J. E. et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286, 42594–42602 (2011).
Henry, C. M. et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 14, 708–722 (2016).
Clancy, D. M. et al. Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing. Cell Rep. 22, 2937–2950 (2018).
Li, N. et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes. J. Immunol. 193, 5140–5148 (2014).
Fukaura, R. & Akiyama, M. Targeting IL-36 in inflammatory skin diseases. BioDrugs 37, 279–293 (2023).
Carrier, Y. et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J. Invest. Dermatol. 131, 2428–2437 (2011).
Madonna, S., Girolomoni, G., Dinarello, C. A. & Albanesi, C. The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis. Int J. Mol. Sci. 20, 3318 (2019).
Foster, A. M. et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 192, 6053–6061 (2014).
Ni, X. et al. IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation. Nat. Immunol. 23, 1577–1587 (2022).
Iznardo, H. & Puig, L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Rev. Clin. Immunol. 17, 187–199 (2021).
Cai, Y. et al. A critical role of the IL-1β-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J. Invest. Dermatol. 139, 146–156 (2019).
Negishi, H., Taniguchi, T. & Yanai, H. The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family. Cold Spring Harb. Perspect. Biol. 10, a028423 (2018).
Mora-Arias, T. & Amezcua-Guerra, L. M. Type III interferons (Lambda Interferons) in rheumatic autoimmune diseases. Arch. Immunol. Ther. Exp. 68, 1 (2020).
Guo, H. et al. SCARB2/LIMP-2 regulates IFN production of plasmacytoid dendritic cells by mediating endosomal translocation of TLR9 and nuclear translocation of IRF7. J. Immunol. 194, 4737–4749 (2015).
Zhang, L. J. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis. Front. Immunol. 10, 1440 (2019).
Toussirot, E., Béreau, M., Bossert, M., Malkoun, I. & Lohse, A. Occurrence of psoriatic arthritis during interferon beta 1a treatment for multiple sclerosis. Case Rep. Rheumatol. 2014, 949317 (2014).
Millán-Pascual, J., Turpín-Fenoll, L., Del Saz-Saucedo, P., Rueda-Medina, I. & Navarro-Muñoz, S. Psoriasis during natalizumab treatment for multiple sclerosis. J. Neurol. 259, 2758–2760 (2012).
Orzan, O. A. et al. An insight on the possible association between inflammatory bowel disease and biologic therapy with IL-17 inhibitors in psoriasis patients. Pharmaceutics 15, 2171 (2023).
Zhou, S. & Yao, Z. Roles of infection in psoriasis. Int J. Mol. Sci. 23, 6955 (2022).
Johnson-Huang, L. M. et al. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J. Invest. Dermatol. 132, 1177–1187 (2012).
Abdallah, M. A., Abdel-Hamid, M. F., Kotb, A. M. & Mabrouk, E. A. Serum interferon-gamma is a psoriasis severity and prognostic marker. Cutis 84, 163–168 (2009).
Albanesi, C., Madonna, S., Gisondi, P. & Girolomoni, G. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front. Immunol. 9, 1549 (2018).
Zhou, X., Chen, Y., Cui, L., Shi, Y. & Guo, C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 13, 81 (2022).
Nestle, F. O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 202, 135–143 (2005).
Zhang, L. J. et al. Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury. Immunity 45, 119–130 (2016).
Simmons, D. P. et al. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188, 3116–3126 (2012).
Tohyama, M. et al. IFN-α enhances IL-22 receptor expression in keratinocytes: a possible role in the development of psoriasis. J. Invest. Dermatol. 132, 1933–1935 (2012).
Georgescu, S. R. et al. Advances in understanding the immunological pathways in psoriasis. Int J. Mol. Sci. 20, 739 (2019).
Young, H. A. Unraveling the pros and cons of interferon-gamma gene regulation. Immunity 24, 506–507 (2006).
Ziblat, A. et al. Interleukin (IL)-23 stimulates IFN-γ secretion by CD56(bright) natural killer cells and enhances IL-18-driven dendritic cells activation. Front. Immunol. 8, 1959 (2017).
Kryczek, I. et al. Induction of IL-17 + T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J. Immunol. 181, 4733–4741 (2008).
Sabat, R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 21, 315–324 (2010).
Lo, Y. H. et al. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J. Dermatol. Sci. 58, 225–227 (2010).
Liu, H. et al. The expression of interleukin-22 and S100A7, A8, A9 mRNA in patients with psoriasis vulgaris. J. Huazhong Univ. Sci. Technol. Med. Sci. 27, 605–607 (2007).
Caproni, M. et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J. Clin. Immunol. 29, 210–214 (2009).
Meephansan, J., Ruchusatsawat, K., Sindhupak, W., Thorner, P. S. & Wongpiyabovorn, J. Effect of methotrexate on serum levels of IL-22 in patients with psoriasis. Eur. J. Dermatol. 21, 501–504 (2011).
Liang, S. C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271–2279 (2006).
Fujita, H. et al. Human Langerhans cells induce distinct IL-22-producing CD4 + T cells lacking IL-17 production. Proc. Natl Acad. Sci. USA 106, 21795–21800 (2009).
Hao, J. Q. Targeting interleukin-22 in psoriasis. Inflammation 37, 94–99 (2014).
Zhang, K., Chen, L., Zhu, C., Zhang, M. & Liang, C. Current knowledge of Th22 cell and IL-22 functions in infectious diseases. Pathogens 12, 176 (2023).
Wolk, K. et al. IL-22 increases the innate immunity of tissues. Immunity 21, 241–254 (2004).
Wolk, K. et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J. Mol. Med. 87, 523–536 (2009).
Saggini, A., Chimenti, S. & Chiricozzi, A. IL-6 as a druggable target in psoriasis: focus on pustular variants. J. Immunol. Res. 2014, 964069 (2014).
Sobolev, V. V., Denisova, E. V., Chebysheva, S. N., Geppe, N. A. & Korsunskaya, I. M. IL-6 gene expression as a marker of pathological state in psoriasis and psoriatic arthritis. Bull. Exp. Biol. Med. 173, 77–80 (2022).
Fujishima, S. et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch. Dermatol. Res. 302, 499–505 (2010).
Blauvelt, A. IL-6 differs from TNF-α: unpredicted clinical effects caused by IL-6 blockade in psoriasis. J. Invest. Dermatol. 137, 541–542 (2017).
Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448–457 (2015).
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M. & Scheller, J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat. Rev. Immunol. 17, 1–16 (2023).
Camporeale, A. & Poli, V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? Front. Biosci. 17, 2306–2326 (2012).
Bodian, M. et al. Fatal evolution of a huge right atrial free-floating thrombus. Clin. Case Rep. 1, 63–65 (2013).
Fritz, Y. et al. Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C + IL-6KO mice. J. Invest. Dermatol. 137, 696–705 (2017).
Midde, H. S. et al. Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis. Clin. Exp. Dermatol. 46, 50–57 (2021).
Schlapbach, C. et al. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci. Transl. Med. 6, 219ra218 (2014).
Theoharides, T. C. et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl Acad. Sci. USA 107, 4448–4453 (2010).
Shakerian, L. et al. IL-33/ST2 axis in autoimmune disease. Cytokine 158, 156015 (2022).
Zhou, X. et al. IL-33-mediated activation of mast cells is involved in the progression of imiquimod-induced psoriasis-like dermatitis. Cell Commun. Signal 21, 52 (2023).
Chen, Z. et al. Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response. Immunology 160, 382–392 (2020).
Suzuki, K. et al. NF-κB1 Contributes to Imiquimod-Induced Psoriasis-Like Skin Inflammation by Inducing Vγ4(+)Vδ4(+)γδT17 Cells. J. Invest. Dermatol. 142, 1639–1649.e1635 (2022).
Andres-Ejarque, R. et al. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nat. Commun. 12, 4741 (2021).
Zhang, H. & Sun, S. C. NF-κB in inflammation and renal diseases. Cell Biosci. 5, 63 (2015).
Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-κB signaling in inflammation. Sig. Transduct. Target Ther. 2, 17023 (2017).
Yu, H., Lin, L., Zhang, Z., Zhang, H. & Hu, H. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct. Target Ther. 5, 209 (2020).
Goldminz, A. M., Au, S. C., Kim, N., Gottlieb, A. B. & Lizzul, P. F. NF-κB: an essential transcription factor in psoriasis. J. Dermatol. Sci. 69, 89–94 (2013).
Stuart, P. E. et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat. Genet. 42, 1000–1004 (2010).
Ali, F. R. & Warren, R. B. Psoriasis and susceptibility to other autoimmune diseases: an outline for the clinician. Expert Rev. Clin. Immunol. 9, 99–101 (2013).
Lorenz, V. N., Schön, M. P. & Seitz, C. S. c-Rel downregulation affects cell cycle progression of human keratinocytes. J. Invest. Dermatol 134, 415–422 (2014).
Fan, T. et al. Treating psoriasis by targeting its susceptibility gene Rel. Clin. Immunol. 165, 47–54 (2016).
Dainichi, T., Matsumoto, R., Mostafa, A. & Kabashima, K. Immune control by TRAF6-mediated pathways of epithelial cells in the EIME (epithelial immune microenvironment). Front. Immunol. 10, 1107 (2019).
Qu, F. et al. TRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activation. Mol. Cell Biol. 32, 3925–3937 (2012).
Tanaka, M. et al. Essential role of CARD14 in murine experimental psoriasis. J. Immunol. 200, 71–81 (2018).
Van Nuffel, E. et al. CARD14-mediated activation of paracaspase MALT1 in keratinocytes: implications for psoriasis. J. Invest. Dermatol. 137, 569–575 (2017).
Jordan, C. T. et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 90, 784–795 (2012).
Tsoi, L. C. et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44, 1341–1348 (2012).
Jordan, C. T. et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am. J. Hum. Genet. 90, 796–808 (2012).
Wang, M. et al. Gain-of-function mutation of Card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity 49, 66–79.e65 (2018).
Mellett, M. et al. CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo. J. Invest. Dermatol. 138, 2010–2023 (2018).
Liang, Y., Sarkar, M. K., Tsoi, L. C. & Gudjonsson, J. E. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 49, 1–8 (2017).
Mauro, C. et al. ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J. Biol. Chem. 281, 18482–18488 (2006).
Ramirez, V. P., Gurevich, I. & Aneskievich, B. J. Emerging roles for TNIP1 in regulating post-receptor signaling. Cytokine Growth Factor Rev. 23, 109–118 (2012).
Guo, G. et al. Gfi1 and Zc3h12c orchestrate a negative feedback loop that inhibits NF-kB activation during inflammation in macrophages. Mol. Immunol. 128, 219–226 (2020).
Liu, L. et al. Zc3h12c inhibits vascular inflammation by repressing NF-κB activation and pro-inflammatory gene expression in endothelial cells. Biochem. J. 451, 55–60 (2013).
Bousoik, E. & Montazeri Aliabadi, H. “Do We Know Jack” about JAK? A closer look at JAK/STAT signaling pathway. Front. Oncol. 8, 287 (2018).
Winthrop, K. L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat. Rev. Rheumatol. 13, 234–243 (2017).
Krueger, J. G., McInnes, I. B. & Blauvelt, A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J. Am. Acad. Dermatol. 86, 148–157 (2022).
Damsky, W. & King, B. A. JAK inhibitors in dermatology: the promise of a new drug class. J. Am. Acad. Dermatol. 76, 736–744 (2017).
Nada, H. R., El Sharkawy, D. A., Elmasry, M. F., Rashed, L. A. & Mamdouh, S. Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study. Arch. Dermatol. Res. 310, 39–46 (2018).
Ishizaki, M. et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int. Immunol. 26, 257–267 (2014).
Tomar, Y., Gorantla, S. & Singhvi, G. Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches. Drug Discov. Today 28, 103465 (2023).
Hald, A. et al. STAT1 expression and activation is increased in lesional psoriatic skin. Br. J. Dermatol. 168, 302–310 (2013).
Sano, S. et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11, 43–49 (2005).
Greb, J. E. et al. Psoriasis. Nat. Rev. Dis. Prim. 2, 16082 (2016).
Kim, E. K. & Choi, E. J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 1802, 396–405 (2010).
Kyriakis, J. M. & Avruch, J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol. Rev. 92, 689–737 (2012).
Yu, X. J. et al. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp. Mol. Pathol. 83, 413–418 (2007).
Krajina, I., Stupin, A., Šola, M. & Mihalj, M. Oxidative stress induced by high salt diet-possible implications for development and clinical manifestation of cutaneous inflammation and endothelial dysfunction in Psoriasis vulgaris. Antioxidants 11, 1269 (2022).
Pasparakis, M., Haase, I. & Nestle, F. O. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14, 289–301 (2014).
Hammouda, M. B., Ford, A. E., Liu, Y. & Zhang, J. Y. The JNK signaling pathway in inflammatory skin disorders and cancer. Cells 9, 857 (2020).
Liang, J. et al. IL-22 down-regulates Cx43 expression and decreases gap junctional intercellular communication by activating the JNK pathway in psoriasis. J. Invest. Dermatol. 139, 400–411 (2019).
Chen, L., Wu, J., Ren, W., Yang, X. & Shen, Z. c-Jun N-terminal kinase (JNK)-phospho-c-JUN (ser63/73) pathway is essential for FOXP3 nuclear translocation in psoriasis. J. Dermatol. Sci. 69, 114–121 (2013).
Afonina, I. S. et al. The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes. EMBO Rep. 17, 914–927 (2016).
Mose, M., Kang, Z., Raaby, L., Iversen, L. & Johansen, C. TNFα- and IL-17A-mediated S100A8 expression is regulated by p38 MAPK. Exp. Dermatol. 22, 476–481 (2013).
Hau, C. S. et al. Visfatin enhances the production of cathelicidin antimicrobial peptide, human β-defensin-2, human β-defensin-3, and S100A7 in human keratinocytes and their orthologs in murine imiquimod-induced psoriatic skin. Am. J. Pathol. 182, 1705–1717 (2013).
Sun, Y. et al. CCN1 promotes IL-1β production in keratinocytes by activating p38 MAPK signaling in psoriasis. Sci. Rep. 7, 43310 (2017).
Funding, A. T., Johansen, C., Kragballe, K. & Iversen, L. Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. J. Invest. Dermatol. 127, 2012–2019 (2007).
Wu, Y. et al. MicroRNA let-7b inhibits keratinocyte differentiation by targeting IL-6 mediated ERK signaling in psoriasis. Cell Commun. Signal 16, 58 (2018).
Chen, J. G., Fan, H. Y., Wang, T., Lin, L. Y. & Cai, T. G. Silencing KRT16 inhibits keratinocyte proliferation and VEGF secretion in psoriasis via inhibition of ERK signaling pathway. Kaohsiung J. Med. Sci. 35, 284–296 (2019).
Yang, J., Sun, L., Han, J., Zheng, W. & Peng, W. DUSP1/MKP-1 regulates proliferation and apoptosis in keratinocytes through the ERK/Elk-1/Egr-1 signaling pathway. Life Sci. 223, 47–53 (2019).
Mercurio, L., Albanesi, C. & Madonna, S. Recent updates on the involvement of PI3K/AKT/mTOR molecular cascade in the pathogenesis of hyperproliferative skin disorders. Front. Med. 8, 665647 (2021).
Chamcheu, J. C. et al. Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in human psoriasis and imiquimod-induced murine psoriasiform dermatitis model. Acta Derm. Venereol. 96, 854–856 (2016).
Huang, T., Lin, X., Meng, X. & Lin, M. Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target? Acta Derm. Venereol. 94, 371–379 (2014).
Zhang, Q. et al. Signaling pathways and targeted therapy for myocardial infarction. Sig. Transduct. Target Ther. 7, 78 (2022).
Zhang, M. & Zhang, X. The role of PI3K/AKT/FOXO signaling in psoriasis. Arch. Dermatol. Res. 311, 83–91 (2019).
Teng, Y. et al. The PI3K/Akt pathway: emerging roles in skin homeostasis and a group of non-malignant skin disorders. Cells 10, 1219 (2021).
Manning, B. D. & Toker, A. AKT/PKB signaling: navigating the network. Cell 169, 381–405 (2017).
Kodani, N. & Nakae, J. Tissue-specific metabolic regulation of FOXO-binding protein: FOXO does not act alone. Cells 9, 702 (2020).
Wang, H., Ran, L. W., Hui, K., Wang, X. Y. & Zheng, Y. Expressions of survivin, PI3K and AKT in keratinocytes in skin lesions and their pathogenic role in psoriasis vulgaris. Nan Fang. Yi Ke Da Xue Xue Bao 37, 1512–1516 (2017).
Zhang, X. Y. et al. Increased activities of Akt in psoriatic epidermis. Chin. J. Dermatol. 42, 413–416 (2009).
Ainali, C. et al. Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics 13, 472 (2012).
Liu, Y., Luo, W. & Chen, S. Comparison of gene expression profiles reveals aberrant expression of FOXO1, Aurora A/B and EZH2 in lesional psoriatic skins. Mol. Biol. Rep. 38, 4219–4224 (2011).
Mitra, A., Raychaudhuri, S. K. & Raychaudhuri, S. P. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 60, 38–42 (2012).
Patel, A. B., Tsilioni, I., Weng, Z. & Theoharides, T. C. TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of mTOR, inhibited by tetramethoxyluteolin. Exp. Dermatol. 27, 135–143 (2018).
Chen, L., Wu, J., Pier, E., Zhao, Y. & Shen, Z. mTORC2-PKBα/Akt1 Serine 473 phosphorylation axis is essential for regulation of FOXP3 Stability by chemokine CCL3 in psoriasis. J. Invest. Dermatol. 133, 418–428 (2013).
Akinduro, O. et al. Constitutive autophagy and nucleophagy during epidermal differentiation. J. Invest. Dermatol. 136, 1460–1470 (2016).
Glaviano, A. et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138 (2023).
Li, Y. et al. Downregulation of PTEN expression in psoriatic lesions. Int J. Dermatol. 53, 855–860 (2014).
Wang, R., Wang, F. F., Cao, H. W. & Yang, J. Y. MiR-223 regulates proliferation and apoptosis of IL-22-stimulated HaCat human keratinocyte cell lines via the PTEN/Akt pathway. Life Sci. 230, 28–34 (2019).
Xu, L. et al. MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis. Biomed. Pharmacother. 90, 524–530 (2017).
Lu, J. et al. CircRAB3B suppresses proliferation, motility, cell cycle progression and promotes the apoptosis of IL-22-induced keratinocytes depending on the regulation of miR-1228-3p/PTEN axis in psoriasis. Autoimmunity 54, 303–312 (2021).
Gudjonsson, J. E. et al. Evidence for altered Wnt signaling in psoriatic skin. J. Invest. Dermatol. 130, 1849–1859 (2010).
Zhang, Y. et al. Wnt/β-Catenin and Wnt5a/Ca pathways regulate proliferation and apoptosis of keratinocytes in psoriasis lesions. Cell Physiol. Biochem. 36, 1890–1902 (2015).
Verma, D. et al. Differential DNA methylation of miRNA-encoding genes in psoriatic epidermis highlights the Wnt pathway. J. Invest. Dermatol. 143, 1594–1597.e14 (2023).
Müller, A. et al. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. J. Clin. Invest. 130, 5765–5781 (2020).
Tsoi, L. C. et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat. Commun. 6, 7001 (2015).
Ben Abdallah, H., Johansen, C. & Iversen, L. Key signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics. Psoriasis 11, 83–97 (2021).
Eyerich, K., Eyerich, S., Hiller, J., Behrendt, H. & Traidl-Hoffmann, C. Chronic mucocutaneous candidiasis, from bench to bedside. Eur. J. Dermatol. 20, 260–265 (2010).
Loo, W. J. et al. Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway. J. Cutan. Med. Surg. 27, 3s–24s (2023).
Tang, L. et al. Transcription factor retinoid-related orphan receptor γt: a promising target for the treatment of psoriasis. Front. Immunol. 9, 1210 (2018).
Ghoreschi, K. et al. TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. J. Dtsch Dermatol. Ges. 19, 1409–1420 (2021).
Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK/STAT signaling pathway: from bench to clinic. Sig. Transduct. Target Ther. 6, 402 (2021).
Hu, X. & Ivashkiv, L. B. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31, 539–550 (2009).
Kalliolias, G. D. & Ivashkiv, L. B. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12, 49–62 (2016).
Brenner, D., Blaser, H. & Mak, T. W. Regulation of tumour necrosis factor signalling: live or let die. Nat. Rev. Immunol. 15, 362–374 (2015).
Dietrich, D. & Gabay, C. Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat. Rev. Rheumatol. 10, 639–640 (2014).
Pohla, L. et al. Hyperproliferation is the main driver of metabolomic changes in psoriasis lesional skin. Sci. Rep. 10, 3081 (2020).
Hiebert, P. & Werner, S. Targeting metabolism to treat psoriasis. Nat. Med. 24, 537–539 (2018).
Holt, V., Morén, B., Fryklund, C., Colbert, R. A. & Stenkula, K. G. Acute cytokine treatment stimulates glucose uptake and glycolysis in human keratinocytes. Cytokine 161, 156057 (2023).
Sylow, L., Kleinert, M., Richter, E. A. & Jensen, T. E. Exercise-stimulated glucose uptake – regulation and implications for glycaemic control. Nat. Rev. Endocrinol. 13, 133–148 (2017).
Hodeib, A. A., Neinaa, Y. M. E., Zakaria, S. S. & Alshenawy, H. A. Glucose transporter-1 (GLUT-1) expression in psoriasis: correlation with disease severity. Int J. Dermatol. 57, 943–951 (2018).
Abdou, A. G., Maraee, A. H., Eltahmoudy, M. & El-Aziz, R. A. Immunohistochemical expression of GLUT-1 and Ki-67 in chronic plaque psoriasis. Am. J. Dermatopathol. 35, 731–737 (2013).
Zhang, Z. et al. Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis. Nat. Med. 24, 617–627 (2018).
Tang, W. et al. HIF-1α may promote glycolysis in psoriasis vulgaris via upregulation of CD147 and GLUT1. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 46, 333–344 (2021).
Liu, Y. Z. et al. Pyruvate kinase M2 mediates glycolysis contributes to psoriasis by promoting keratinocyte proliferation. Front. Pharm. 12, 765790 (2021).
Veras, F. P. et al. Pyruvate kinase M2 mediates IL-17 signaling in keratinocytes driving psoriatic skin inflammation. Cell Rep. 41, 111897 (2022).
Kono, M. et al. Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight 4, e127395 (2019).
Damasceno, L. E. A. et al. PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation. J. Exp. Med. 217, e20190613 (2020).
Certo, M., Tsai, C. H., Pucino, V., Ho, P. C. & Mauro, C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat. Rev. Immunol. 21, 151–161 (2021).
Claps, G. et al. The multiple roles of LDH in cancer. Nat. Rev. Clin. Oncol. 19, 749–762 (2022).
Le Floch, R. et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl Acad. Sci. USA 108, 16663–16668 (2011).
Baba, M., Inoue, M., Itoh, K. & Nishizawa, Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem. Biophys. Res Commun. 374, 111–116 (2008).
Walters, D. K., Arendt, B. K. & Jelinek, D. F. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle 12, 3175–3183 (2013).
Koguchi-Yoshioka, H. et al. Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis. J. Dermatol. Sci. 103, 109–115 (2021).
Lu, H. et al. CD147 is highly expressed on peripheral blood neutrophils from patients with psoriasis and induces neutrophil chemotaxis. J. Dermatol. 37, 1053–1056 (2010).
Peng, C. et al. Epidermal CD147 expression plays a key role in IL-22-induced psoriatic dermatitis. Sci. Rep. 7, 44172 (2017).
Okubo, A. et al. CD147 is essential for the development of psoriasis via the induction of Th17 cell differentiation. Int. J. Mol. Sci. 23, 177 (2021).
Rambold, A. S. & Pearce, E. L. Mitochondrial dynamics at the interface of immune cell metabolism and function. Trends Immunol. 39, 6–18 (2018).
Fan, J. X. et al. New conditions of HPLC analysis for separation and quantification of simple organic acids of tricarboxylic acid cycle in psoriasis. Acta Chromatographica. 33, 322–332 (2021).
Fan, J. X., et al. Quantitative detection and metabolic profile analysis of metabolites of tricarboxylic acid cycle and amino acids in psoriasis serum before and after receiving monoclonal antibody treatment by one-pot GC-MS derivatization. Int. J. Mass. Spectrom, 460 116478 (2021).
Ghoreschi, K. et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 208, 2291–2303 (2011).
Mrowietz, U. et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J. Eur. Acad. Dermatol. Venereol. 32, 3–14 (2018).
Bambouskova, M. et al. Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis. Nature 556, 501–504 (2018).
Nastasi, C. et al. Inhibition of succinate dehydrogenase activity impairs human T cell activation and function. Sci. Rep. 11, 1458 (2021).
Kamleh, M. A. et al. LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment. J. Proteome Res. 14, 557–566 (2015).
Chen, C. et al. Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis. Theranostics 11, 754–767 (2021).
Goetzman, E. S. & Prochownik, E. V. The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues. Front. Endocrinol. 9, 129 (2018).
Nakaya, M. et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 40, 692–705 (2014).
Xia, X. et al. GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis. J. Clin. Invest. 130, 5180–5196 (2020).
Cibrian, D. et al. CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis. Nat. Immunol. 17, 985–996 (2016).
Cibrian, D. et al. Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation. J. Allergy Clin. Immunol. 145, 199–214.e111 (2020).
Poitelon, Y., Kopec, A. M. & Belin, S. Myelin fat facts: an overview of lipids and fatty acid metabolism. Cells 9, 812 (2020).
Feingold, K. R. The outer frontier: the importance of lipid metabolism in the skin. J. Lipid Res. 50, S417–S422 (2009).
Chibowska, M. [Role of serum lipids in pseriasis]. Przegl Dermatol 57, 255–260 (1970).
Hammarström, S. et al. Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc. Natl Acad. Sci. USA 72, 5130–5134 (1975).
Sorokin, A. V. et al. Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J. Invest. Dermatol. 138, 1518–1528 (2018).
Kim, S. et al. Phytosphingosine stimulates the differentiation of human keratinocytes and inhibits TPA-induced inflammatory epidermal hyperplasia in hairless mouse skin. Mol. Med. 12, 17–24 (2006).
Myśliwiec, H. et al. Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients. Arch. Dermatol. Res. 309, 79–86 (2017).
Schaper, K. et al. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis. J. Dermatol. Sci. 71, 29–36 (2013).
Jeon, S. et al. Inhibition of sphingosine 1-phosphate lyase activates human keratinocyte differentiation and attenuates psoriasis in mice. J. Lipid Res. 61, 20–32 (2020).
Shin, S. H. et al. Inhibiting sphingosine kinase 2 derived-sphingosine-1-phosphate ameliorates psoriasis-like skin disease via blocking Th17 differentiation of naïve CD4 T lymphocytes in mice. Acta Derm. Venereol. 99, 594–601 (2019).
Vaclavkova, A. et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 384, 2036–2045 (2014).
Liu, P. et al. Lipidomic profiling reveals metabolic signatures in psoriatic skin lesions. Clin. Immunol. 246, 109212 (2023).
Zeng, C. et al. Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis. Gigascience 6, 1–11 (2017).
Lei, L. et al. Lysophosphatidic acid mediates the pathogenesis of psoriasis by activating keratinocytes through LPAR5. Sig. Transduct. Target Ther. 6, 19 (2021).
Decara, J. et al. Peroxisome proliferator-activated receptors: experimental targeting for the treatment of inflammatory bowel diseases. Front. Pharm. 11, 730 (2020).
Schuster, C. et al. S1PR4-dependent CCL2 production promotes macrophage recruitment in a murine psoriasis model. Eur. J. Immunol. 50, 839–845 (2020).
Schaper, K., Kietzmann, M. & Bäumer, W. Sphingosine-1-phosphate differently regulates the cytokine production of IL-12, IL-23 and IL-27 in activated murine bone marrow derived dendritic cells. Mol. Immunol. 59, 10–18 (2014).
Dillmann, C. et al. S1PR4 signaling attenuates ILT 7 internalization to limit IFN-α production by human plasmacytoid dendritic cells. J. Immunol. 196, 1579–1590 (2016).
Baeyens, A. A. L. & Schwab, S. R. Finding a way out: S1P signaling and immune cell migration. Annu. Rev. Immunol. 38, 759–784 (2020).
Pietrzak, A., Michalak-Stoma, A., Chodorowska, G. & Szepietowski, J. C. Lipid disturbances in psoriasis: an update. Mediators Inflamm. 2010, 535612 (2010).
Xiang, Z., Yang, Y., Chang, C. & Lu, Q. The epigenetic mechanism for discordance of autoimmunity in monozygotic twins. J. Autoimmun. 83, 43–50 (2017).
Generali, E., Ceribelli, A., Stazi, M. A. & Selmi, C. Lessons learned from twins in autoimmune and chronic inflammatory diseases. J. Autoimmun. 83, 51–61 (2017).
Li, J. et al. Multi-omics study in monozygotic twins confirm the contribution of de novo mutation to psoriasis. J. Autoimmun. 106, 102349 (2020).
Yu, J. et al. Pathogenesis, multi-omics research, and clinical treatment of psoriasis. J. Autoimmun. 133, 102916 (2022).
Yi, J. Z. & McGee, J. S. Epigenetic-modifying therapies: an emerging avenue for the treatment of inflammatory skin diseases. Exp. Dermatol. 30, 1167–1176 (2021).
Surace, A. E. A. & Hedrich, C. M. The role of epigenetics in autoimmune/inflammatory disease. Front. Immunol. 10, 1525 (2019).
Mattei, A. L., Bailly, N. & Meissner, A. DNA methylation: a historical perspective. Trends Genet 38, 676–707 (2022).
Roberson, E. D. et al. A subset of methylated CpG sites differentiate psoriatic from normal skin. J. Invest. Dermatol. 132, 583–592 (2012).
Zhou, F. et al. Epigenome-wide association data implicates DNA methylation-mediated genetic risk in psoriasis. Clin. Epigenetics 8, 131 (2016).
Zhang, P. et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J. Autoimmun. 41, 17–24 (2013).
Zhou, F. et al. Epigenome-wide association analysis identified nine skin DNA methylation loci for psoriasis. J. Invest. Dermatol. 136, 779–787 (2016).
Zhang, P., Su, Y., Chen, H., Zhao, M. & Lu, Q. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J. Dermatol. Sci. 60, 40–42 (2010).
Yooyongsatit, S. et al. Patterns and functional roles of LINE-1 and Alu methylation in the keratinocyte from patients with psoriasis vulgaris. J. Hum. Genet. 60, 349–355 (2015).
Suarez, N. A., Macia, A. & Muotri, A. R. LINE-1 retrotransposons in healthy and diseased human brain. Dev. Neurobiol. 78, 434–455 (2018).
Guengerich, F. P. & Cheng, Q. Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharm. Rev. 63, 684–699 (2011).
Sheng, Y. et al. CYP2S1 might regulate proliferation and immune response of keratinocyte in psoriasis. Epigenetics 16, 618–628 (2021).
Wang, Z. et al. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation. Autophagy 17, 529–552 (2021).
Verma, D., Ekman, A. K., Bivik Eding, C. & Enerbäck, C. Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis. J. Invest. Dermatol. 138, 1088–1093 (2018).
Chandra, A., Senapati, S., Roy, S., Chatterjee, G. & Chatterjee, R. Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clin. Epigenetics 10, 108 (2018).
Xu, X. et al. Genome-wide DNA methylation of Munro’s microabscess reveals the epigenetic regulation in the pathogenesis of psoriasis. Front. Immunol. 13, 1057839 (2022).
Witte, K. et al. Increased presence and differential molecular imprinting of transit amplifying cells in psoriasis. J. Mol. Med. 98, 111–122 (2020).
Liu, Y., Cui, S., Sun, J., Yan, X. & Han, D. Identification of potential biomarkers for psoriasis by DNA methylation and gene expression datasets. Front. Genet. 12, 722803 (2021).
Deng, M. et al. DNA methylation markers in peripheral blood for psoriatic arthritis. J. Dermatol. Sci. 108, 39–47 (2022).
Liu, L. et al. Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis. Clin. Immunol. 250, 109294 (2023).
Sabari, B. R., Zhang, D., Allis, C. D. & Zhao, Y. Metabolic regulation of gene expression through histone acylations. Nat. Rev. Mol. Cell Biol. 18, 90–101 (2017).
Fu, Y., Yu, J., Li, F. & Ge, S. Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification. J. Exp. Clin. Cancer Res. 41, 144 (2022).
Li, X. et al. Lactate metabolism in human health and disease. Sig. Transduct. Target Ther. 7, 305 (2022).
Zheng, Q., Osunsade, A. & David, Y. Protein arginine deiminase 4 antagonizes methylglyoxal-induced histone glycation. Nat. Commun. 11, 3241 (2020).
Zhang, X. et al. Molecular basis for hierarchical histone de-β-hydroxybutyrylation by SIRT3. Cell Discov. 5, 35 (2019).
Millán-Zambrano, G., Burton, A., Bannister, A. J. & Schneider, R. Histone post-translational modifications – cause and consequence of genome function. Nat. Rev. Genet. 23, 563–580 (2022).
Gibson, F. et al. Epigenetic dysregulation in autoimmune and inflammatory skin diseases. Clin. Rev. Allergy Immunol. 63, 447–471 (2022).
Zhang, P., Su, Y., Zhao, M., Huang, W. & Lu, Q. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur. J. Dermatol. 21, 552–557 (2011).
Ekman, A. K. & Enerbäck, C. Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis. Br. J. Dermatol. 174, 424–426 (2016).
Li, H. et al. Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation. Nat. Commun. 9, 1420 (2018).
Samuelov, L. et al. Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis. Exp. Dermatol. 31, 567–576 (2022).
Thatikonda, S., Pooladanda, V., Sigalapalli, D. K. & Godugu, C. Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation. Cell Death Dis. 11, 21 (2020).
Ariel, F. et al. R-loop mediated trans action of the APOLO long noncoding RNA. Mol. Cell 77, 1055–1065.e1054 (2020).
Anastasiadou, E., Jacob, L. S. & Slack, F. J. Non-coding RNA networks in cancer. Nat. Rev. Cancer 18, 5–18 (2018).
Kopp, F. & Mendell, J. T. Functional classification and experimental dissection of long noncoding RNAs. Cell 172, 393–407 (2018).
Yang, L., Wilusz, J. E. & Chen, L. L. Biogenesis and regulatory roles of circular RNAs. Annu. Rev. Cell Dev. Biol. 38, 263–289 (2022).
Winkle, M., El-Daly, S. M., Fabbri, M. & Calin, G. A. Noncoding RNA therapeutics – challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629–651 (2021).
Wu, R. et al. MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation. J. Clin. Invest. 128, 2551–2568 (2018).
Yang, L. et al. Hsa_circ_0004287 inhibits macrophage-mediated inflammation in an N(6)-methyladenosine-dependent manner in atopic dermatitis and psoriasis. J. Allergy Clin. Immunol. 149, 2021–2033 (2022).
Agbu, P. & Carthew, R. W. MicroRNA-mediated regulation of glucose and lipid metabolism. Nat. Rev. Mol. Cell Biol. 22, 425–438 (2021).
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F. & Goel, A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat. Rev. Gastroenterol. Hepatol. 17, 111–130 (2020).
Gao, H. et al. MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH. Cell Metab. 34, 978–990.e974 (2022).
Zhu, J. et al. Stem cell-homing hydrogel-based miR-29b-5p delivery promotes cartilage regeneration by suppressing senescence in an osteoarthritis rat model. Sci. Adv. 8, eabk0011 (2022).
Dopytalska, K., Ciechanowicz, P., Wiszniewski, K., Szymańska, E. & Walecka, I. The role of epigenetic factors in psoriasis. Int J. Mol. Sci. 22, 9294 (2021).
Li, H., Zhou, L. & Dai, J. Retinoic acid receptor-related orphan receptor RORα regulates differentiation and survival of keratinocytes during hypoxia. J. Cell Physiol. 233, 641–650 (2018).
Li, J. et al. Inhibition of miR-155 attenuates CD14(+) monocyte-mediated inflammatory response and oxidative stress in psoriasis through TLR4/MyD88/NF-κB signaling pathway. Clin. Cosmet. Investig. Dermatol 15, 193–201 (2022).
Luo, Q. et al. Silencing of miR‑155 suppresses inflammatory responses in psoriasis through inflammasome NLRP3 regulation. Int J. Mol. Med. 42, 1086–1095 (2018).
Guo, W. et al. Ebosin ameliorates psoriasis-like inflammation of mice via miR-155 targeting tnfaip3 on IL-17 pathway. Front. Immunol. 12, 662362 (2021).
Wang, H. et al. The miR-155/GATA3/IL37 axis modulates the production of proinflammatory cytokines upon TNF-α stimulation to affect psoriasis development. Exp. Dermatol. 29, 647–658 (2020).
Liu, Y. et al. MiR-155 inhibits TP53INP1 expression leading to enhanced glycolysis of psoriatic mesenchymal stem cells. J. Dermatol. Sci. 105, 142–151 (2022).
Abdallah, F. & Pichon, C. Evidence on the direct correlation between miR-31 and IL-22 axis in IMQ-induced psoriasis. Exp. Dermatol. 28, 1336–1340 (2019).
Wang, M. J. et al. Metabolic rewiring in keratinocytes by miR-31-5p identifies therapeutic intervention for psoriasis. EMBO Mol. Med. 15, e15674 (2023).
Wang, Q. et al. Levels of miR-31 and its target genes in dermal mesenchymal cells of patients with psoriasis. Int J. Dermatol. 58, 198–204 (2019).
Wang, J. K., Wang, Z. & Li, G. MicroRNA-125 in immunity and cancer. Cancer Lett. 454, 134–145 (2019).
Raaby, L. et al. Changes in mRNA expression precede changes in microRNA expression in lesional psoriatic skin during treatment with adalimumab. Br. J. Dermatol. 173, 436–447 (2015).
Su, F., Jin, L. & Liu, W. MicroRNA-125a correlates with decreased psoriasis severity and inflammation and represses keratinocyte proliferation. Dermatology 237, 568–578 (2021).
Yang, Z. et al. STAT3/SH3PXD2A-AS1/miR-125b/STAT3 positive feedback loop affects psoriasis pathogenesis via regulating human keratinocyte proliferation. Cytokine 144, 155535 (2021).
Pan, M., Huang, Y., Zhu, X., Lin, X. & Luo, D. miR‑125b‑mediated regulation of cell proliferation through the Jagged‑1/Notch signaling pathway by inhibiting BRD4 expression in psoriasis. Mol. Med. Rep. 19, 5227–5236 (2019).
Chen, H. et al. CircVAPA contributes to hyper-proliferation and inflammation of keratinocytes through miR-125b-5p/sirt6 axis in psoriasis. Int. Immunopharmacol. 115, 109632 (2023).
Chowdhari, S., Sardana, K. & Saini, N. miR-4516, a microRNA downregulated in psoriasis inhibits keratinocyte motility by targeting fibronectin/integrin α9 signaling. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 3142–3152 (2017).
Chowdhari, S. & Saini, N. hsa-miR-4516 mediated downregulation of STAT3/CDK6/UBE2N plays a role in PUVA induced apoptosis in keratinocytes. J. Cell Physiol. 229, 1630–1638 (2014).
Srivastava, A. et al. Cross-talk between IFN-γ and TWEAK through miR-149 amplifies skin inflammation in psoriasis. J. Allergy Clin. Immunol. 147, 2225–2235 (2021).
Xu, J. et al. IRF3-binding lncRNA-ISIR strengthens interferon production in viral infection and autoinflammation. Cell Rep. 37, 109926 (2021).
Zou, Y. et al. Long noncoding RNA LERFS negatively regulates rheumatoid synovial aggression and proliferation. J. Clin. Invest. 128, 4510–4524 (2018).
Akıncılar, S. C. et al. NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NFκB in colitis. Gut 70, 1857–1871 (2021).
Yan, J. et al. Long noncoding RNA expression profile and functional analysis in psoriasis. Mol. Med. Rep. 19, 3421–3430 (2019).
Tsoi, L. C. et al. Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. Genome Biol. 16, 24 (2015).
Li, S. et al. LncRNA NORAD engages in psoriasis by binding to miR-26a to regulate keratinocyte proliferation. Autoimmunity 54, 129–137 (2021).
Qiao, M., Li, R., Zhao, X., Yan, J. & Sun, Q. Up-regulated lncRNA-MSX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7. Exp. Cell Res. 363, 243–254 (2018).
Duan, Q. et al. LncRNA RP6-65G23.1 accelerates proliferation and inhibits apoptosis via p-ERK1/2/p-AKT signaling pathway on keratinocytes. J. Cell Biochem. 121, 4580–4589 (2020).
Gao, J. et al. Knockdown of lncRNA MIR31HG inhibits cell proliferation in human HaCaT keratinocytes. Biol. Res. 51, 30 (2018).
Jia, H. Y. et al. LncRNA MEG3 influences the proliferation and apoptosis of psoriasis epidermal cells by targeting miR-21/caspase-8. BMC Mol. Cell Biol. 20, 46 (2019).
Lin, J. et al. LOC285194 inhibits proliferation of human keratinocytes through regulating miR-616/GATA3 pathway. Mol. Cell Probes 53, 101598 (2020).
Gupta, R. et al. Landscape of long noncoding RNAs in psoriatic and healthy skin. J. Invest. Dermatol. 136, 603–609 (2016).
He, R. et al. Identification of a long noncoding RNA TRAF3IP2-AS1 as key regulator of IL-17 signaling through the SRSF10-IRF1-Act1 axis in autoimmune diseases. J. Immunol. 206, 2353–2365 (2021).
Kristensen, L. S. et al. The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 20, 675–691 (2019).
Liu, C. X. & Chen, L. L. Circular RNAs: characterization, cellular roles, and applications. Cell 185, 2016–2034 (2022).
Chen, L. L. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat. Rev. Mol. Cell Biol. 21, 475–490 (2020).
Li, B. et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat. Commun. 12, 295 (2021).
Liu, B. et al. An inducible circular RNA circKcnt2 inhibits ILC3 activation to facilitate colitis resolution. Nat. Commun. 11, 4076 (2020).
Qiao, M. et al. Circular RNA expression profile and analysis of their potential function in psoriasis. Cell Physiol. Biochem. 50, 15–27 (2018).
Yang, L. et al. hsa_circ_0003738 inhibits the suppressive function of tregs by targeting miR-562/IL-17A and miR-490-5p/IFN-γ signaling pathway. Mol. Ther. Nucleic Acids 21, 1111–1119 (2020).
Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. 20, 608–624 (2019).
Oerum, S., Meynier, V., Catala, M. & Tisné, C. A comprehensive review of m6A/m6Am RNA methyltransferase structures. Nucleic Acids Res. 49, 7239–7255 (2021).
Wang, Y. N. & Jin, H. Z. Transcriptome-wide m(6)A methylation in skin lesions from patients with psoriasis vulgaris. Front. Cell Dev. Biol. 8, 591629 (2020).
Xian, J. et al. N(6)-methyladenosine-modified long non-coding RNA AGAP2-AS1 promotes psoriasis pathogenesis via miR-424-5p/AKT3 axis. J. Dermatol. Sci. 105, 27–36 (2022).
Xiao, Z. et al. METTL3-mediated m6A methylation orchestrates mRNA stability and dsRNA contents to equilibrate γδ T1 and γδ T17 cells. Cell Rep. 42, 112684 (2023).
Strauss, H. Zur Lehre von der neurogenen und der thyreogenen Glykosurie (Schluss aus No. 18.). Dtsch. Medizinische WOCHENSCHR. – DEUT MED WOCHENSCHR 23, 309–312 (1897).
Greenberg, R. et al. Comorbidities in patients with palmoplantar plaque psoriasis. J. Am. Acad. Dermatol. 84, 639–643 (2021).
Ruiz Genao, D. P. et al. Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. Br. J. Dermatol. 187, 817–820 (2022).
Zhang, L., Wang, Y., Qiu, L. & Wu, J. Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis. BMC Med. 20, 421 (2022).
Srivastava, A. K. et al. Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities. J. Autoimmun. 118, 102614 (2021).
Fu, Y., Lee, C. H. & Chi, C. C. Association of psoriasis with colorectal cancer. J. Am. Acad. Dermatol. 85, 1429–1436 (2021).
Vaengebjerg, S., Skov, L., Egeberg, A. & Loft, N. D. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 156, 421–429 (2020).
Quaranta, M. et al. Differential contribution of CDKAL1 variants to psoriasis, Crohn’s disease and type II diabetes. Genes Immun. 10, 654–658 (2009).
Wang, H. et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp. Dermatol. 26, 1112–1117 (2017).
Buerger, C. et al. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J. Invest Dermatol. 132, 2206–2214 (2012).
Rohm, T. V., Meier, D. T., Olefsky, J. M. & Donath, M. Y. Inflammation in obesity, diabetes, and related disorders. Immunity 55, 31–55 (2022).
Wolf, N. et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J. Med. Genet. 45, 114–116 (2008).
Cottone, M., Sapienza, C., Macaluso, F. S. & Cannizzaro, M. Psoriasis and inflammatory bowel disease. Dig. Dis. 37, 451–457 (2019).
Kakurai, M. et al. Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. Br. J. Dermatol. 161, 1232–1238 (2009).
Kowalczyk, A., Kleniewska, P., Kolodziejczyk, M., Skibska, B. & Goraca, A. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch. Immunol. Ther. Exp. 63, 41–52 (2015).
Alouffi, S., Faisal, M., Alatar, A. A. & Ahmad, S. Oxidative modification of LDL by various physicochemical techniques: its probable role in diabetes coupled with CVDs. Biomed. Res. Int. 2018, 7390612 (2018).
Shih, C. M. et al. The roles of lipoprotein in psoriasis. Int J. Mol. Sci. 21, 859 (2020).
Bentzon, J. F., Otsuka, F., Virmani, R. & Falk, E. Mechanisms of plaque formation and rupture. Circ. Res. 114, 1852–1866 (2014).
Karbach, S. et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler. Thromb. Vasc. Biol. 34, 2658–2668 (2014).
Barros, G., Duran, P., Vera, I. & Bermúdez, V. Exploring the links between obesity and psoriasis: a comprehensive review. Int. J. Mol. Sci. 23, 7499 (2022).
Kong, Y. et al. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis. Lipids Health Dis. 18, 171 (2019).
González-Parra, S. & Daudén, E. Psoriasis and depression: the role of inflammation. Actas Dermosifiliogr. 110, 12–19 (2019).
Lada, G., Chinoy, H., Talbot, P. S., Warren, R. B. & Kleyn, C. E. The relationship of depression and systemic inflammation in psoriasis: findings from the UK biobank. J. Invest. Dermatol. 143, 1091–1094 (2023).
Marek-Jozefowicz, L. et al. The brain-skin axis in psoriasis-psychological, psychiatric, hormonal, and dermatological aspects. Int. J. Mol. Sci. 23, 669 (2022).
Kamiya, K., Kishimoto, M., Sugai, J., Komine, M. & Ohtsuki, M. Risk factors for the development of psoriasis. Int. J. Mol. Sci. 20, 4347 (2019).
Pace, T. W. & Miller, A. H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. NY Acad. Sci. 1179, 86–105 (2009).
Svoboda, S. A., Ghamrawi, R. I., Owusu, D. A. & Feldman, S. R. Treatment goals in psoriasis: which outcomes matter most? Am. J. Clin. Dermatol. 21, 505–511 (2020).
Nast, A. & Schmitt, J. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J. Am. Acad. Dermatol. 68, 1040–1041 (2013).
Nast, A. et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J. Eur. Acad. Dermatol. Venereol. 34, 2461–2498 (2020).
McInnes, I. B. et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 395, 1496–1505 (2020).
Elewski, B. E. et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 78, 90–99.e1 (2018).
Castela, E. et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J. Eur. Acad. Dermatol. Venereol. 26, 36–46 (2012).
Hengge, U. R., Ruzicka, T., Schwartz, R. A. & Cork, M. J. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 54, 1–15 (2006).
Kim, E. S. & Frampton, J. E. Calcipotriol/betamethasone dipropionate foam: a review in plaque psoriasis. Drugs 76, 1485–1492 (2016).
McCormack, P. L. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs 71, 709–730 (2011).
Sugarman, J. L. et al. A phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J. Drugs Dermatol. 16, 197–204 (2017).
Freeman, A. K. et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol. 48, 564–568 (2003).
Kalb, R. E., Strober, B., Weinstein, G. & Lebwohl, M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J. Am. Acad. Dermatol. 60, 824–837 (2009).
Flytström, I., Stenberg, B., Svensson, A. & Bergbrant, I. M. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br. J. Dermatol. 158, 116–121 (2008).
Goldfarb, M. T. et al. Acitretin improves psoriasis in a dose-dependent fashion. J. Am. Acad. Dermatol. 18, 655–662 (1988).
Elmets, C. A. et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J. Am. Acad. Dermatol. 81, 775–804 (2019).
Archier, E. et al. Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J. Eur. Acad. Dermatol. Venereol. 26, 11–21 (2012).
Hoy, S. M. & Scott, L. J. Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis. Drugs 67, 2609–2633 (2007).
Tobin, A.-M. & Kirby, B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19, 47–57 (2005).
Leonardi, C. L. et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014–2022 (2003).
Tyring, S. et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367, 29–35 (2006).
Mease, P. J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385–390 (2000).
Sterry, W. et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340, c147 (2010).
Antoni, C. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150–1157 (2005).
Gottlieb, A. B. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534–542 (2004).
Reich, K. et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366, 1367–1374 (2005).
Barker, J. et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br. J. Dermatol. 165, 1109–1117 (2011).
de Vries, A. C. et al. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. Br. J. Dermatol. 176, 624–633 (2017).
Menter, A. et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J. Am. Acad. Dermatol. 58, 106–115 (2008).
Gordon, K. et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J. Am. Acad. Dermatol. 66, 241–251 (2012).
Mease, P. et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N. Engl. J. Med. 377, 1537–1550 (2017).
McInnes, I. B. et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N. Engl. J. Med. 384, 1227–1239 (2021).
Kremenevski, I., Sander, O., Sticherling, M., Raithel, M. & LastName, F. M. Paradoxical reactions to biologicals in chronic inflammatory systemic diseases. Dtsch Arztebl Int. 119, 88–95 (2022).
Fania, L. et al. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development. J. Pathol. Clin. Res. 6, 55–68 (2020).
Krueger, J. G. et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J. Allergy Clin. Immunol. 144, 750–763 (2019).
Gordon, K. B. et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. 375, 345–356 (2016).
McInnes, I. B. et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386, 1137–1146 (2015).
Lebwohl, M. et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N. Engl. J. Med. 373, 1318–1328 (2015).
Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 370, 2295–2306 (2014).
Mease, P. J., Helliwell, P. S., Hjuler, K. F., Raymond, K. & McInnes, I. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann. Rheum. Dis. 80, 185–193 (2021).
Gordon, K. B. et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 397, 475–486 (2021).
European medicines agency. Bimzelx: overview (European medicines agency, 2021).
Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2021 (Pharmaceuticals and Medical Devices Agency, 2022).
McInnes, I. B. et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 401, 25–37 (2023).
Reich, K. et al. Bimekizumab versus secukinumab in plaque psoriasis. N. Engl. J. Med. 385, 142–152 (2021).
Warren, R. B. et al. Bimekizumab versus adalimumab in plaque psoriasis. N. Engl. J. Med. 385, 130–141 (2021).
Yeilding, N. et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann. NY Acad. Sci. 1222, 30–39 (2011).
Kimball, A. B. et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br. J. Dermatol. 166, 861–872 (2012).
Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675–1684 (2008).
McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780–789 (2013).
Gossec, L. et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann. Rheum. Dis. 81, 823–830 (2022).
Letarouilly, J.-G. et al. Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatology 60, 2773–2782 (2021).
Rich, P. et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br. J. Dermatol. 170, 398–407 (2014).
Gossec, L. et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Ann. Rheum. Dis. 82, 496–506 (2022).
Puig, L., Morales-Múnera, C. E., López-Ferrer, A. & Geli, C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 225, 14–17 (2012).
Markham, A. Guselkumab: first global approval. Drugs 77, 1487–1492 (2017).
Deodhar, A. et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1115–1125 (2020).
McInnes, I. B. et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 73, 604–616 (2021).
Reich, K. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 394, 831–839 (2019).
Reich, K. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J. Am. Acad. Dermatol. 76, 418–431 (2017).
Papp, K. et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br. J. Dermatol. 173, 930–939 (2015).